Drug Trial Radar · NCT05971732
The Effects of Ferric Derisomaltose in Patients With Acute Heart Failure and Iron Deficiency on Exercise Capacity and Quality of Life(COREVIVE-HFrEF)
Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
146
Planned (sponsor's estimate)
Start
Aug 1, 2023
Primary completion
Aug 1, 2027
Study completion Aug 1, 2027
Sponsor
- Lead sponsor
- China-Japan Friendship HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 2, 2023
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will address whether the additional use of Ferric Derisomaltose on top of standard care will improve exercise capacity and quality of life in patients with acute heart failure and iron deficiency. One group of participants will receive treatment with Ferric Derisomaltose and the other group will receive normal saline 0.9% as placebo.
Conditions
- Heart Failure With Reduced Ejection Fraction
- Iron Deficiency
- Acute Heart Failure
Interventions
Ferric derisomaltoseDrug
After baseline assessments patients will be randomised in a 1:1 ratio to receive ferric derisomaltose IV or placebo (normal saline). In the Treatment group, Ferric derisomaltose will be administered according to the dosing schedule.
PlaceboDrug
In the placebo group, patients will receive the equivalent number of normal saline injections.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in 6-minute walking distanceTime frame: Up to 3 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
China-Japan Friendship Hospital
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.